Lunai Bioworks receives U.S. patent for AI architecture in disease subtyping
Lunai Bioworks said it received U.S. Patent No. 12,369,861 for debiasing data in drug discovery predictions. The patent covers multimodal data standardization and structural bias removal before predictive modeling.
Lunai Bioworks, Inc. on Feb. 19, 2026 announced the issuance of U.S. Patent No. 12,369,861, titled "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions." The company said the patent protects the foundational first step of its proprietary closed-loop disease reverse engineering platform, multimodal data standardization and structural bias removal prior to predictive modeling. The issuance of this patent and the advancement of additional applications represent tangible execution against a strategy focused on strengthening the core technology platform, expanding a defensible intellectual property moat, and building scalable AI infrastructure capable of supporting long-term pharmaceutical collaborations.
The company said precision disease subtyping begins with clean, standardized multimodal data. It said the patent protects the critical first step in its closed-loop AI architecture, increasing confidence in biomarker discovery, disease stratification, and gene network mapping across its CNS and biodefense programs.
According to the company, hidden dataset bias and fragmentation across genomic, clinical, imaging, and phenotypic sources can distort biomarker discovery and reduce translational reliability. The patented architecture systematically detects, standardizes, and removes structural bias across multimodal inputs before downstream artificial intelligence modeling begins.
The company said that by protecting this core data layer, it strengthens its ability to accurately identify biologically coherent patient subtypes and trace those subtypes to the gene networks most strongly associated with each disease type.
Lunai Bioworks said it is an AI-driven biotechnology company advancing precision therapeutics in central nervous system disorders and oncology, as well as solutions for biodefense. The company said its proprietary platform integrates diverse biomedical datasets to generate actionable insights for therapeutic development and clinical advancement.